New brain scan could spot Parkinson's earlier

NCT ID NCT07685873

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests whether a special imaging agent called 18F-FPyCO/SMBT-1 can help diagnose Parkinson's disease and related conditions by detecting a brain enzyme called MAO-B. About 200 adults with suspected or confirmed Parkinson's will receive a single injection of the agent and undergo PET/CT or MRI scans. The goal is to see how well the scans identify disease-related changes in the brain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
18F-FPyCO/SMBT-1 (imaging agent)
What this could lead to
If successful, this imaging method could help doctors diagnose Parkinson's disease more accurately and earlier.
What could go wrong
This is an early diagnostic study, not a treatment. The imaging agent may not reliably distinguish Parkinson's from other conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of University of Science and Technology of China

    RECRUITING

    Hefei, Anhui, 230000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Tianjin Medical University General Hospital

    RECRUITING

    Tianjin, Tian, 300052, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.